Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion

Futura Medical (FUM) Competitors

Futura Medical logo
GBX 0.70 -0.05 (-6.67%)
As of 12:22 PM Eastern
Compare

FUM vs. IXI, RLM, NSCI, CIZ, and GENF

Should you buy Futura Medical stock or one of its competitors? MarketBeat compares Futura Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Futura Medical include IXICO (IXI), Realm Therapeutics (RLM), NetScientific (NSCI), Cizzle Biotechnology (CIZ), and Genflow Biosciences (GENF). These companies are all part of the "biotechnology" industry.

How does Futura Medical compare to IXICO?

Futura Medical (LON:FUM) and IXICO (LON:IXI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

IXICO has higher revenue and earnings than Futura Medical. IXICO is trading at a lower price-to-earnings ratio than Futura Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Futura Medical£1.70M2.40-£3.88M-£2.78N/A
IXICO£6.53M3.00-£3.58M-£1.85N/A

IXICO has a net margin of -25.27% compared to Futura Medical's net margin of -534.62%. IXICO's return on equity of -13.74% beat Futura Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Futura Medical-534.62% -310.00% -26.59%
IXICO -25.27%-13.74%-10.40%

1.0% of Futura Medical shares are held by institutional investors. Comparatively, 4.7% of IXICO shares are held by institutional investors. 16.0% of Futura Medical shares are held by insiders. Comparatively, 6.0% of IXICO shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Futura Medical has a beta of 0.013, meaning that its share price is 99% less volatile than the broader market. Comparatively, IXICO has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market.

In the previous week, IXICO had 5 more articles in the media than Futura Medical. MarketBeat recorded 6 mentions for IXICO and 1 mentions for Futura Medical. Futura Medical's average media sentiment score of 0.75 beat IXICO's score of -0.06 indicating that Futura Medical is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Futura Medical
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
IXICO
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

IXICO beats Futura Medical on 10 of the 13 factors compared between the two stocks.

How does Futura Medical compare to Realm Therapeutics?

Realm Therapeutics (LON:RLM) and Futura Medical (LON:FUM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Realm Therapeutics has a net margin of 0.00% compared to Futura Medical's net margin of -534.62%. Realm Therapeutics' return on equity of 0.00% beat Futura Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Realm TherapeuticsN/A N/A N/A
Futura Medical -534.62%-310.00%-26.59%

In the previous week, Futura Medical had 1 more articles in the media than Realm Therapeutics. MarketBeat recorded 1 mentions for Futura Medical and 0 mentions for Realm Therapeutics. Futura Medical's average media sentiment score of 0.75 beat Realm Therapeutics' score of 0.00 indicating that Futura Medical is being referred to more favorably in the news media.

Company Overall Sentiment
Realm Therapeutics Neutral
Futura Medical Positive

Realm Therapeutics has higher earnings, but lower revenue than Futura Medical. Futura Medical is trading at a lower price-to-earnings ratio than Realm Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Realm Therapeutics£501.92K0.00N/A-£17.50N/A
Futura Medical£1.70M2.40-£3.88M-£2.78N/A

1.0% of Futura Medical shares are owned by institutional investors. 16.0% of Futura Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Futura Medical beats Realm Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Futura Medical compare to NetScientific?

NetScientific (LON:NSCI) and Futura Medical (LON:FUM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

NetScientific has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market. Comparatively, Futura Medical has a beta of 0.013, meaning that its stock price is 99% less volatile than the broader market.

In the previous week, Futura Medical had 1 more articles in the media than NetScientific. MarketBeat recorded 1 mentions for Futura Medical and 0 mentions for NetScientific. Futura Medical's average media sentiment score of 0.75 beat NetScientific's score of 0.00 indicating that Futura Medical is being referred to more favorably in the news media.

Company Overall Sentiment
NetScientific Neutral
Futura Medical Positive

14.7% of NetScientific shares are held by institutional investors. Comparatively, 1.0% of Futura Medical shares are held by institutional investors. 42.4% of NetScientific shares are held by company insiders. Comparatively, 16.0% of Futura Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

NetScientific has higher earnings, but lower revenue than Futura Medical. Futura Medical is trading at a lower price-to-earnings ratio than NetScientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NetScientific£1.45M0.00-£2.64M-£0.11N/A
Futura Medical£1.70M2.40-£3.88M-£2.78N/A

NetScientific has a net margin of -182.91% compared to Futura Medical's net margin of -534.62%. NetScientific's return on equity of -13.70% beat Futura Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
NetScientific-182.91% -13.70% -9.42%
Futura Medical -534.62%-310.00%-26.59%

Summary

NetScientific beats Futura Medical on 8 of the 12 factors compared between the two stocks.

How does Futura Medical compare to Cizzle Biotechnology?

Futura Medical (LON:FUM) and Cizzle Biotechnology (LON:CIZ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Futura Medical has a beta of 0.013, suggesting that its share price is 99% less volatile than the broader market. Comparatively, Cizzle Biotechnology has a beta of 0.068073176, suggesting that its share price is 93% less volatile than the broader market.

Cizzle Biotechnology has a net margin of 0.00% compared to Futura Medical's net margin of -534.62%. Cizzle Biotechnology's return on equity of 104.99% beat Futura Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Futura Medical-534.62% -310.00% -26.59%
Cizzle Biotechnology N/A 104.99%-31.72%

1.0% of Futura Medical shares are held by institutional investors. Comparatively, 0.0% of Cizzle Biotechnology shares are held by institutional investors. 16.0% of Futura Medical shares are held by company insiders. Comparatively, 72.2% of Cizzle Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Futura Medical had 1 more articles in the media than Cizzle Biotechnology. MarketBeat recorded 1 mentions for Futura Medical and 0 mentions for Cizzle Biotechnology. Futura Medical's average media sentiment score of 0.75 beat Cizzle Biotechnology's score of 0.00 indicating that Futura Medical is being referred to more favorably in the media.

Company Overall Sentiment
Futura Medical Positive
Cizzle Biotechnology Neutral

Cizzle Biotechnology has lower revenue, but higher earnings than Futura Medical. Cizzle Biotechnology is trading at a lower price-to-earnings ratio than Futura Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Futura Medical£1.70M2.40-£3.88M-£2.78N/A
Cizzle BiotechnologyN/AN/A-£2.81K-£0.17N/A

Summary

Futura Medical and Cizzle Biotechnology tied by winning 6 of the 12 factors compared between the two stocks.

How does Futura Medical compare to Genflow Biosciences?

Genflow Biosciences (LON:GENF) and Futura Medical (LON:FUM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

0.1% of Genflow Biosciences shares are owned by institutional investors. Comparatively, 1.0% of Futura Medical shares are owned by institutional investors. 47.5% of Genflow Biosciences shares are owned by insiders. Comparatively, 16.0% of Futura Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Genflow Biosciences has a beta of 2.108, suggesting that its stock price is 111% more volatile than the broader market. Comparatively, Futura Medical has a beta of 0.013, suggesting that its stock price is 99% less volatile than the broader market.

Genflow Biosciences has higher earnings, but lower revenue than Futura Medical. Genflow Biosciences is trading at a lower price-to-earnings ratio than Futura Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
Futura Medical£1.70M2.40-£3.88M-£2.78N/A

Genflow Biosciences has a net margin of 840.76% compared to Futura Medical's net margin of -534.62%. Genflow Biosciences' return on equity of 377.33% beat Futura Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences840.76% 377.33% -58.66%
Futura Medical -534.62%-310.00%-26.59%

In the previous week, Futura Medical had 1 more articles in the media than Genflow Biosciences. MarketBeat recorded 1 mentions for Futura Medical and 0 mentions for Genflow Biosciences. Futura Medical's average media sentiment score of 0.75 beat Genflow Biosciences' score of 0.00 indicating that Futura Medical is being referred to more favorably in the news media.

Company Overall Sentiment
Genflow Biosciences Neutral
Futura Medical Positive

Summary

Genflow Biosciences and Futura Medical tied by winning 6 of the 12 factors compared between the two stocks.

Get Futura Medical News Delivered to You Automatically

Sign up to receive the latest news and ratings for FUM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FUM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FUM vs. The Competition

Export
MetricFutura MedicalBiotechnology IndustryMedical SectorLON Exchange
Market Cap£4.07M£464.72M£6.29B£2.76B
Dividend Yield4.55%3.86%2.80%6.14%
P/E Ratio-0.253.8020.64365.16
Price / Sales2.407,437.39580.0287,649.01
Price / Cash20.4313.1327.4827.89
Price / Book0.2784.129.757.64
Net Income-£3.88M-£96.07M£3.55B£5.89B
7 Day Performance3.86%1.91%-1.59%0.12%
1 Month Performance-41.18%0.51%-3.51%0.28%
1 Year Performance-92.55%69.33%30.08%83.48%

Futura Medical Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FUM
Futura Medical
N/AGBX 0.70
-6.7%		N/A-91.2%£4.07M£1.70MN/A12
IXI
IXICO
N/AGBX 7
+3.7%		N/A-29.7%£15.26M£6.53MN/A89
RLM
Realm Therapeutics
N/AN/AN/AN/A£13.41M£501.92KN/AN/A
NSCI
NetScientific
N/AN/AN/AN/A£12.81M£1.45MN/A26
CIZ
Cizzle Biotechnology
N/AGBX 3
-6.3%		N/A+96.0%£11.89MN/AN/A4

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:FUM) was last updated on 5/19/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel